Recently, Marra et al. proved that CD47 expression by IHC varies according to genotype with higher expression in AML patients with favorable risk, especially those with CBFβ/MYH11 and NPM1 mutation [11]. This evidence concerns the gene MYH11 and acute myeloid leukemia.